Re. The commercial agreement, the internal funding approvals...

Re. The commercial agreement, the internal funding approvals tells us they are happy with price, which means there really can't be much more negotiation, considering major renegotiations could result in variations and therefore would need more funding. Would be surprised if this wasn't finalised in Feb. But who really knows.

My favourite thing about this announcement is the 3rd party agreement. Membrane technology is moving quickly, so it is good to see Parkway is collaborative with these techs. From the brief description it is a pre-treatment to aMes. iBC is a pre-treatment to conventional Ro and UF so I am guessing the new technology sits between RO/UF and aMes.

disappointed with cash burn. Staff costs near matches revenue and cost of goods sold is all deficit basically. I do understand that some of the COGS is inventory, but would prefer they break this down in future for transparency.

hopefully we break even at some point this year.